Martingale Asset Management L P Boosts Stake in Gilead Sciences, Inc. (GILD)
Martingale Asset Management L P grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 1.7% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,327 shares of the biopharmaceutical company’s stock after acquiring an additional 896 shares during the period. Martingale Asset Management L P’s holdings in Gilead Sciences were worth $3,532,000 at the end of the most recent reporting period.
Other hedge funds also recently bought and sold shares of the company. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp raised its position in shares of Gilead Sciences by 95.7% during the 4th quarter. Her Majesty the Queen in Right of the Province of Alberta as represented by Alberta Investment Management Corp now owns 554,083 shares of the biopharmaceutical company’s stock worth $34,658,000 after purchasing an additional 271,000 shares during the last quarter. Chilton Capital Management LLC grew its stake in Gilead Sciences by 3.5% in the 4th quarter. Chilton Capital Management LLC now owns 16,468 shares of the biopharmaceutical company’s stock worth $1,030,000 after acquiring an additional 555 shares during the period. Nicholas Company Inc. grew its stake in Gilead Sciences by 2.7% in the 4th quarter. Nicholas Company Inc. now owns 506,760 shares of the biopharmaceutical company’s stock worth $31,697,000 after acquiring an additional 13,500 shares during the period. Sectoral Asset Management Inc grew its stake in Gilead Sciences by 59.6% in the 4th quarter. Sectoral Asset Management Inc now owns 424,890 shares of the biopharmaceutical company’s stock worth $26,577,000 after acquiring an additional 158,750 shares during the period. Finally, AIMZ Investment Advisors LLC grew its stake in Gilead Sciences by 39.9% in the 4th quarter. AIMZ Investment Advisors LLC now owns 53,738 shares of the biopharmaceutical company’s stock worth $3,361,000 after acquiring an additional 15,333 shares during the period. Institutional investors own 78.71% of the company’s stock.
In other Gilead Sciences news, Director Richard James Whitley sold 9,534 shares of the business’s stock in a transaction on Monday, April 1st. The shares were sold at an average price of $65.48, for a total value of $624,286.32. Following the transaction, the director now owns 34,669 shares in the company, valued at approximately $2,270,126.12. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director John Francis Cogan sold 2,700 shares of the business’s stock in a transaction on Wednesday, March 27th. The stock was sold at an average price of $64.14, for a total transaction of $173,178.00. Following the completion of the transaction, the director now owns 57,560 shares in the company, valued at approximately $3,691,898.40. The disclosure for this sale can be found here. Insiders sold a total of 28,602 shares of company stock worth $1,863,445 in the last quarter. 0.20% of the stock is currently owned by company insiders.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $1.76 EPS for the quarter, topping analysts’ consensus estimates of $1.53 by $0.23. Gilead Sciences had a net margin of 26.40% and a return on equity of 37.98%. The firm had revenue of $5.28 billion for the quarter, compared to analyst estimates of $5.29 billion. During the same quarter in the previous year, the business posted $1.48 EPS. The firm’s revenue was up 3.8% compared to the same quarter last year. Sell-side analysts forecast that Gilead Sciences, Inc. will post 6.6 EPS for the current fiscal year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 27th. Shareholders of record on Friday, June 14th will be issued a $0.63 dividend. The ex-dividend date of this dividend is Thursday, June 13th. This represents a $2.52 dividend on an annualized basis and a yield of 3.96%. Gilead Sciences’s dividend payout ratio is currently 40.98%.
Several analysts have commented on the stock. Zacks Investment Research raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $69.00 target price for the company in a research note on Tuesday, April 23rd. Credit Suisse Group assumed coverage on shares of Gilead Sciences in a research note on Monday, May 20th. They issued a “neutral” rating and a $70.00 target price for the company. Mizuho set a $88.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Friday, May 17th. Oppenheimer set a $85.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a research note on Tuesday, March 19th. Finally, BidaskClub raised shares of Gilead Sciences from a “sell” rating to a “hold” rating in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, eight have issued a hold rating and sixteen have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $79.54.
WARNING: This piece was posted by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2019/06/04/martingale-asset-management-l-p-boosts-stake-in-gilead-sciences-inc-gild.html.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.